2023 World Conference on Lung Cancer (Posters)-EP11.02. First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis

EP11.02. First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference analyzed the efficacy and safety of the combination treatment of sintilimab and anlotinib compared to platinum-based chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). The study, called SUNRISE, included previously untreated NSCLC patients who were negative for EGFR/ALK/ROS1 genetic mutations.<br /><br />The results showed that patients receiving the sintilimab-anlotinib combination had a significantly improved objective response rate (ORR) compared to those receiving chemotherapy. The ORR was 52.2% in the sintilimab-anlotinib group compared to 29.8% in the chemotherapy group. The duration of response (DoR) was also longer in the sintilimab-anlotinib group, with a median DoR of 21.4 months compared to 13.0 months in the chemotherapy group.<br /><br />Furthermore, the sintilimab-anlotinib combination demonstrated improved progression-free survival (PFS) compared to chemotherapy. The median PFS in the sintilimab-anlotinib group was 12.6 months, while it was 5.7 months in the chemotherapy group. No significant differences in overall survival (OS) were observed between the two groups.<br /><br />The safety profile of the sintilimab-anlotinib combination was manageable, with no new safety signals observed. Grade 3-4 treatment-related adverse events (TRAE) were less frequent in the sintilimab-anlotinib group compared to the chemotherapy group. The most frequently observed TRAEs in the sintilimab-anlotinib group were hyponatremia, anemia, and hypothyroidism, mainly of Grade 1-2 severity.<br /><br />Based on these findings, the study suggests that the combination of sintilimab and anlotinib could be a potential chemo-free option for the first-line treatment of metastatic NSCLC. The combination therapy demonstrated durable efficacy benefits and a manageable safety profile in treatment-naive patients with metastatic NSCLC. Further studies and follow-up are needed to assess long-term survival outcomes and confirm the efficacy and safety of this combination therapy.

Asset Subtitle

Tianqing Chu

Meta Tag

Speaker Tianqing Chu

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

WCLC 2023

sintilimab

anlotinib

platinum-based chemotherapy

metastatic non-small cell lung cancer

NSCLC

EGFR/ALK/ROS1 genetic mutations

objective response rate

duration of response

progression-free survival